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A single blind, randomized, placebo-controlled, single-center phase I clinical trial of a CD8 T-cell peptide
epitope vaccine against infectious mononucleosis was conducted with 14 HLA B*0801-positive, Epstein-Barr
virus (EBV)-seronegative adults. The vaccine comprised the HLA B*0801-restricted peptide epitope FLRGR
AYGL and tetanus toxoid formulated in a water-in-oil adjuvant, Montanide ISA 720. FLRGRAYGL-specific
responses were detected in 8/9 peptide-vaccine recipients and 0/4 placebo vaccine recipients by gamma
interferon enzyme-linked immunospot assay and/or limiting-dilution analysis. The same T-cell receptor V
CDR3 sequence that is found in FLRGRAYGL-specific T cells from most EBV-seropositive individuals could
also be detected in the peripheral blood of vaccine recipients. The vaccine was well tolerated, with the main side
effect being mild to moderate injection site reactions. After a 2- to 12-year follow-up, 1/2 placebo vaccinees who
acquired EBV developed infectious mononucleosis, whereas 4/4 vaccinees who acquired EBV after completing
peptide vaccination seroconverted asymptomatically. Single-epitope vaccination did not predispose individuals
to disease, nor did it significantly influence development of a normal repertoire of EBV-specific CD8 T-cell
responses following seroconversion.
Epstein-Barr Virus (EBV) is a human gammaherpesvirus
that is usually transmitted orally during childhood and infects
more than 90% of the world’s population. The virus establishes
a lifelong latent infection in B cells and is controlled in healthy
seropositive individuals by CD8  T lymphocytes that rec-
ognize latent and lytic EBV antigens (38, 44). When infection
with EBV is delayed until adolescence or adulthood, as is
common in many Western countries, individuals have a 26 to
74% chance of developing glandular fever or infectious mono-
nucleosis (IM) (19). IM is an acute, self-limiting disorder as-
sociated with fatigue, fever, sore throat, and generalized
lymphadenopathy and is characterized by a pronounced blood
monocytosis. The severity of symptoms varies from mild flu-
like symptoms for a few weeks to prolonged and debilitating
disease lasting several months (19), and in rare cases the dis-
ease can be fatal (59). IM caused by EBV has also been
associated with increased risk of multiple sclerosis and
Hodgkin’s lymphoma (26, 41). In Western countries the inci-
dence of IM has been estimated to be 45/100,000 per annum in
the general community. However, the incidence is much higher
among adolescents (15 to 19 years), at 320 to 370/100,000 per
annum (18), and thus often affects young people at a critical
time in their studies. The disease is less common in developing
countries, where 90% of people generally seroconvert
asymptomatically to EBV during childhood. In Western coun-
tries the number of children entering adolescence without be-
ing infected with EBV has been estimated at 10 to 20%. How-
ever, this figure may be increasing with improvements in living
standards. In the Tokyo region this percentage has recently
been estimated to have reached 50% by 2006 (57). Although
ganciclovir has been used in severe cases and in immunocom-
promised patients (1) and corticosteroids are sometimes used
(15), there are currently no treatments recommended for rou-
tine use in IM.
The ability of many individuals’ immune systems to control
primary EBV infections without IM has prompted efforts to-
ward the design of an IM vaccine (38, 39). Two approaches
have been taken. The first involves a vaccine based on the
major surface glycoprotein of EBV, gp350. This vaccine was
originally conceived to induce neutralizing antibodies; how-
ever, antibody responses do not appear to correlate with pro-
tection, with some evidence suggesting that gp350-specific CD4
T-cell responses might mediate protection (40). The second
approach seeks to generate EBV-specific CD8 T cells that
control the expansion of EBV-infected B cells after infection,
thereby promoting asymptomatic seroconversion rather than
preventing infection (38, 39). Such T cells are not only strongly
implicated in controlling EBV in healthy individuals but have
also been successfully used to treat EBV-associated posttrans-
plant lymphoproliferative disease (PTLD) by adoptive transfer
(29, 47, 49). Many EBV-specific CD8 T cells recognize
epitopes from the EBV nuclear antigens (EBNAs) (44). How-
ever, the association of these proteins with B-cell transforma-
tion precludes, and their large size complicates, their use in
recombinant protein-based vaccines (54). A CD8 T-cell
epitope-based approach was thus pursued (39). Here we de-
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scribe the results of the first phase I CD8 T-cell epitope-
based EBV vaccine trial. The vaccine comprised the HLA
B*0801-restricted CD8 T-cell epitope FLRGRAYGL (FLR)
from the latent antigen EBNA3 (9, 10) and tetanus toxoid (TT)
as a source of CD4 T-cell help formulated in the water-in-oil
adjuvant, Montanide ISA 720. This adjuvant has been success-
fully used to induce peptide-epitope-specific CD8 T-cell re-
sponses in mice (20, 48) and has been used in several human
vaccine trials (23, 36, 46, 62).
The primary aim of this trial was to establish that CD8
T-cell epitope-based vaccination of EBV seronegative individ-
uals was safe in the context of a primary EBV infection. IM is
characterized by a high viral load and a pronounced lympho-
cytosis dominated by EBV-specific T cells (13, 14, 24). Asymp-
tomatic seroconversion does not appear to be associated with
a lymphocytosis, despite significant viral loads, suggesting that
IM arises from an overreaction of T-cell responses (53).
Whether a vaccine-induced EBV-specific memory T-cell re-
sponse would subsequently expand following a primary infec-
tion and thereby promote lymphocytosis and IM remains an
important question. In addition, since an FLR-based vaccine
would induce CD8 T-cell responses only to this single
epitope, it also remains to be established whether immu-
nodominance and/or immunodomination effects (17, 50)
would narrow the immune response following a subsequent
primary EBV infection to this epitope. Rapid recovery from
IM symptoms has been correlated with broad T-cell reactivity
to multiple CD8 T-cell epitopes within lytic and latent anti-
gens, whereas protracted illness was associated with a narrowly
focused response (4). It has also been suggested that epitope-
based vaccines might induce tolerance against the vaccine
epitope and thus prevent a normal response to that epitope
from developing (2, 61). This trial illustrates that single-
epitope vaccination does not promote disease or predispose
individuals to aberrant EBV-specific CD8 T-cell response
after seroconversion, indicating that an epitope-based ap-
proach for IM or PTLD vaccines is both feasible and safe.
MATERIALS AND METHODS
Study design. The single-blind, randomized, placebo-controlled phase I (safety
and immunogenicity) EBV vaccine trial was conducted at the Queensland Insti-
tute of Medical Research (QIMR), Australia and was approved by The Bancroft
Centre Research Ethics Committee and conducted under the Australian Ther-
apeutic Goods Administration CTN scheme. Volunteers were recruited from
QIMR and the University of Queensland and were screened for HLA B*0801
status and EBV infection by serology. The initial HLA screening was performed
by fluorescence-activated cell sorter (FACS) analysis using the HLA B*0801
monoclonal antibody (clone 59HA-1; One Lambda Inc.) and was later confirmed
by full class I tissue typing (Princess Alexandra Hospital tissue typing facility,
Brisbane, Australia). Serological testing for EBV capsid antibody (VCA) was
initially done by immunofluorescence microscopy (37) and later confirmed by
enzyme-linked immunosorbent assay specific for VCA immunoglobulin G (IgG)
and IgM and EBNA IgG (Queensland Medical Laboratory, Brisbane, Queens-
land, Australia). The inclusion criteria for the trial were EBV-seronegative and
HLA B*0801-positive status. To avoid adverse reactions to TT (27, 33), volun-
teers were excluded if they had anti-TT titers of above 5 IU/ml (Queensland
Medical Laboratory) or a history of marked reaction to previous TT injections.
Volunteers were also excluded if 2 weeks prior to vaccination (i) either full and
differential blood counts, CD4/CD8 lymphocyte count, full blood biochemistry
(including aspartate transaminase, alanine aminotransferase, gamma glutamyl
transferase, urea, and creatinine), antinuclear factor, direct Coombs test, or
urine protein was outside the normal range; (ii) females tested positive for serum
or urine human chorionic gonadotropin; (iii) volunteers were seropositive for
EBV, human immunodeficiency virus, or hepatitis B virus (tests performed by
Queensland Health Pathology Services, Royal Brisbane Hospital); or (iv) the
medical history or physical examination revealed clinical abnormalities. Separate
information sessions and consent forms were provided for screening and enroll-
ment into the trial.
Fourteen healthy, EBV-seronegative, HLA B*0801-positive, 18- to 50-year-
old volunteers (seven females and seven males) were enrolled in the trial. They
were randomly assigned by a computer-generated list into vaccine (n  10, with
8 to be immunized with 5 g and 2 with 50 g peptide) and placebo (n  4)
groups (Table 1). Vaccine recipients were observed for 6 h following each
immunization and contacted by telephone after 1 week. Clinical assessment was
performed and blood was collected for immunological screening (including EBV
serology and T-cell responses) before each injection and at 2, 4, 8, 10, and 12
weeks and 6, 12, and 24 months after each vaccination. Two vaccinations were
offered, the first at day 0 and the second at week 8. Where possible, volunteers
were also followed up after 8 to 12 years to test for EBV seroconversion and
inquire whether they had suffered from IM since vaccination.
The EBV vaccine. The vaccine consisted of the synthetic peptide, FLR (9),
mixed with TT in 5 mM phosphate buffer-isotonic saline and emulsified (3:7
[wt/wt]) with the water-in-oil adjuvant Montanide ISA 720 (Seppic, Paris,
France) (20). The FLR peptide was chemically synthesized under GMP condi-
tions (Auspep Ltd.). Two peptide doses were tested, 5 and 50 g per vaccine
dose, with the placebo vaccine containing no peptide. The peptide and placebo
vaccines also contained 1.35 Lyme factor/ml (0.675 Lyme factor/dose) TT (CSL
Ltd.) and thiomersal (0.01% [wt/vol]) (CSL Ltd.). Stoppered glass vials were
filled with the vaccines under nitrogen by CSL Ltd. Volunteers were given 0.5 ml
of vaccine per injection subcutaneously into the thigh.
Formal toxicology was undertaken by Pharmatox. Two 500-l subcutaneous
(day 1 and 15) injections of the vaccine (with 50 g of peptide) given to five male
and five female rats and guinea pigs failed to show clinical signs of toxicity over
29 days. Upon necroscopy, organ histology and blood hematology and biochem-
istry were not clinically different from those of animals injected with saline. The
same dose also passed pyrogenicity testing in three rabbits. The vaccine showed
no activity in the Ames test or sister chromatid exchange assay. The peptide was
stable in the vaccine for 2 years at 4°C and was extracted from the vaccine by
vigorous shaking with chloroform–0.1% trifluoroacetic acid in distilled water
(1.5:1, vol/vol). The recovered peptide (in the aqueous phase) was analyzed by
high-pressure liquid chromatography and was fully active in chromium release
assays (9).
LCLs and PHA blasts. EBV-transformed lymphoblastoid cell lines (LCLs)
were established from each vaccinee’s peripheral blood mononuclear cells
(PBMC) by exogenous virus transformation of peripheral B cells using the
QIMR Wil strain of virus (43). LCLs were maintained in medium comprising
RPMI 1640 (Gibco), 2 mM glutamine (ICN Biomed. Aust. Pty Ltd., Seven Hills,
Australia), 100 IU/ml penicillin and 100 mg/ml streptomycin (CSL Ltd., Mel-
bourne, Australia), and 10% fetal calf serum (QIMR). Phytohemagglutinin
(PHA) blasts were generated and maintained as described previously (31).
Ex vivo ELISPOT assay. PBMC were separated by Ficoll density gradient
centrifugation and frozen in 10% dimethyl sulfoxide and 90% fetal calf serum
using the Cryo 1° freezing container (Nalgene). Gamma interferon (IFN-)
enzyme-linked immunospot (ELISPOT) assays were performed as described
before (5) using the FLR peptide. T-cell responses to the HLA B8-restricted
epitopes QAKWRLQTL (QAK) and RAKFKQLL (RAK), and the HLA A2-
restricted epitopes LLDFVRFMGV, CLGGLLTMV, YLLEMLWRL, YLQQN
WWTL, GLCTLVAML, and ILIYNGWYA were also assessed for the indicated
individuals. Peptides for in vitro assays were synthesized by Chiron Mimotopes
(Melbourne, Australia).
LDA. The limiting-dilution analysis (LDA) was performed as described pre-
viously (30). Briefly, PBMC from vaccinees were distributed in twofold dilutions
from 6.25 	 103 to 5 	 104 cells per well in round-bottom microtiter plates and
stimulated with irradiated (2,000 rads) FLR-sensitized autologous PBMC or
irradiated (8,000 rads) autologous LCLs. On day 10, each of the 24 replicate
microcultures for each dilution was split into two replicates and used as effectors
in a standard 5-h 51Cr release assay against autologous PHA blasts sensitized
with and without peptide epitope. Wells were scored as positive when the percent
specific chromium release for peptide-sensitized target cells exceeded the mean
release from control wells by 3 standard deviations. T-cell frequency was calcu-
lated by the method of maximum-likelihood estimation.
Bulk cultures. Polyclonal T-cell effectors were generated from 2 	 106 PBMC
stimulated (on day 0 and day 7) either with irradiated (8,000 rads) autologous
LCLs (responder/stimulator ratio of 20:1) or with PBMC sensitized with syn-
thetic peptides (10 g/ml) (responder/stimulator ratio of 4:1). On day 10, these
bulk effectors were used in a standard 51Cr release assay against peptide-sensi-
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tized autologous PHA blasts at a 20:1 effector-to-target ratio as described pre-
viously (8).
T-cell receptor (TCR) sequencing. Total RNA was extracted from frozen
PBMC or frozen bulk culture pellets containing 5 million cells by using TRIzol
reagent (Invitrogen). The RNA pellets were resuspending in 20 l of diethyl
pyrocarbonate-treated double-distilled water (ICN) and were each added to a
single-tube one-step reverse transcription-PCR (RT-PCR) system (Invitogen),
with the addition of the TRBV7-8 family-specific forward primer (5
-TGAAGC
TCAAACTAGACAAATCG-3
) and the FLR-specific reverse CDR3-2-7 prim-
ers (5
-CTGGTAGGCCTGBCCTAAGCTGCTGGC-3
 and 5
-AGTACTGCT
CGTAGGCCTGBCC-3
). The RT-PCR cycling was performed at 50°C for 30
min and 94°C for 2 min. The PCR cycling was performed at 94°C for 15 s, 55°C
for 30 s, and 68°C for 1 min for 40 cycles and at 68°C for 5 min for 1 cycle. The
PCR products were cloned into the pGEM-T vector system (Promega) and
transformed into DH5 cells (Invitrogen). White colonies (six to eight) were
picked and placed into a M13 miniscreen PCR instrument. The PCR products
were then sequenced with the ABI Prism Big Dye Terminator reaction kit
(Applied Biosystems).
TCR RNA viability was evaluated in all samples with a total TCR constant-
region RT-PCR with the addition of the TCR constant-region forward primer
C5
 (5
-CGTGTTCCCACCCGAGGTCGC-3
) and the TCR constant-region
reverse primer CB (5
-ATTCACCCACCAGCTCAGCTCCACG-3
) into the
one-step RT-PCR system (Invitogen). The PCR cycling conditions were identical
to those for the FLR CDR3-specific PCR described above.
Major histocompatibility complex (MHC)-peptide multimer analysis. PBMC
or T-cell lines were incubated for 30 min at 4°C with an HLA B*0801-FLR or
HLA B*0801-RAK phycoerythrin-labeled pentamer (ProImmune, Oxford,
United Kingdom). Cells were then washed and labeled for 30 min at 4°C with
Tri-color-labeled anti-human CD8 (Caltag, Burlingame, CA), allophycocyanin-
labeled anti-human CD3 (BD Pharmingen, San Diego, CA), and one of fluores-
cein isothiocyanate-labeled anti-human-CD27 (Caltag, Burlingame, CA), anti-
human CD28 (BD Pharmingen, San Diego, CA), anti-human CD45RA
(Beckman-Coulter, Fullerton, CA), anti-human CD45RO (Beckman-Coulter,
Fullerton, CA), or anti-human CD62L (Caltag, Burlingame, CA). Cells were
then washed twice and analyzed on a four-color FACSCalibur using CellQuest
software (Becton Dickinson, Mountain View, CA).
RESULTS
Volunteer selection. A total of 1,075 resident students from
the University of Queensland and staff members from QIMR
were screened within a span of 5 years (1994 to 1999), and 25%
were shown to be EBV seronegative. Of these, 72 (6.7%) were
found to be EBV seronegative and HLA B*0801 positive dur-
ing the initial screening. Ultimately 14 volunteers (1.5%) were
enrolled in the trial. The main reasons for exclusion were
anti-TT antibody titers of5 IU/ml, EBV seroconversion prior
to final enrollment, and subjects declining to continue.
Vaccination, adverse events, and seroconversion. Fourteen
volunteers were vaccinated, including eight with 5 g peptide
(volunteers designated #01, #02, #04, #05, #06, #07, #08,
and #09), two with 50 g peptide (#013 and #014), and four
with placebo (#03, #010, #011, and #012). Three subjects
(#07, #08, and #011) were not given the second vaccination
because of an increase in anti-TT titers beyond 5 IU/ml. One
subject (#014) was not given the second vaccination due to
EBV seroconversion. One subject (#09) declined the second
dose of vaccine because of the discomfort following the first
dose (Table 1). The vaccine was well tolerated in most volun-
teers, and no serious adverse events were seen throughout the
trial period. Side effects were restricted to self-limiting, mild to
moderate injection site reactions, which are summarized in
Table 2.
Two vaccinees (#04 and #08) were EBV seronegative at 52
weeks but had seroconverted by week 104, and one vaccinee
(#09) was seronegative at 12 weeks but had seroconverted by
week 26 (Table 1). These seroconversion events were asymp-
tomatic, and no adverse events were experienced during these
TABLE 1. Vaccination summary for vaccine recipients, EBV seroconversion, and IM
Vaccine Vaccinerecipient
EBV
seroconversion
(wk of test)
IM or asymptomatic
EBV serology
VCA
EBNA IgG
IgM IgG
Peptide
5 g #01 No (412) Negative Negative Negative
#02 Yes (628) Asymptomatic Negative Positive Positive
#04 Yes (104) Asymptomaticd Low positive Moderate Negative
#05 No (542) Negative Negative Negative
#06 No (523) Negative Negative Negative
#07a No (520) Negative Negative Negative
#08a Yes (104) Asymptomaticd Negative Moderate Positive
#09b Yes (26) Asymptomaticd Negative Moderate Negative
50 g #13 No (421) Negative Negative Negative
#14c Yes (8) ?d,e Positive Borderlinef Negative
Placebo #03 No (585) Negative Negative Negative
#10 No (494) Negative Negative Negative
#11a Yes (438) Asymptomatic Negative Borderlineg Not tested
#12 Yes (392) IM, treating doctor notified
a Second immunization not given due to high anti-TT antibody titers.
b Declined second immunization.
c Second immunization not given due to EBV seroconversion.
d Lymphocyte count within normal range at time of serology test.
e Diagnosis unclear, possible mild IM or tonsillitis (see text).
f Borderline. VCA IgM usually lasts for 1 to 2 months. Anti-EBNA IgG responses usually appear after 2 to 6 months.
g FLR- and RAK-specific T-cell expansions seen by FACS (data not shown), confirming EBV-positive status.
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periods. A further vaccinee, #02, seroconverted between
weeks 104 and 628 with no history of IM. One of the placebo-
vaccinated volunteers (#12) was diagnosed with IM by their
general practitioner using symptoms and serology at week 392
(Table 1).
Vaccinee #14 was found to be EBV seropositive at 8 weeks
(Table 1) and at that time had significant responses against
FLR (20/106 lymphocytes), RAK (480/106), and QAK 72/106)
as measured by LDA. No responses were detected at weeks 2
and 4 (data not shown). The incubation period for EBV has
been reported to be 38 days for one individual (56), which
suggests that vaccinee 14 became infected within a few weeks
of the first immunization. This vaccinee complained of a severe
sore throat and fatigue, which lasted about 2 to 3 weeks and
began at about week 7. No time off work was taken, biochem-
istry was normal, and no significant lymphocytosis was present
at week 4 or 8. At week 4 the CD4 and CD8 counts were 1.64 	
109 and 0.45 	 109/liter, respectively, and this changed to 0.89 	
109 and 1.77 	 109/liter at week 8. This clinical picture may
represent mild IM; however, this vaccinee had a history of
repeated tonsillitis and was prescribed penicillin by her general
practitioner. To try to determine whether vaccinee 14 had IM,
interleukin-15 (IL-15) receptor status was determined, as this
receptor has been reported to be permanently down regulated
in T cells from individuals who have had IM (45). However, in
contrast to the findings of Sauce et al. (45), we found no
differences in IL-15 receptor status between several EBV-se-
ronegative individuals, healthy EBV-seropositive individuals,
and individuals recovered from IM (data not shown). Using
monoclonal antibodies 151303 and 151307 (R&D Systems), 0.1
to 4% of CD4 T cells and 3 to 15% of CD8 T cells were
IL-15 receptor positive in all groups and in vaccinee #14 (data
not shown). The IL-15 receptor profile thus does not appear to
be a reliable indicator of past IM.
Induction of FLR-specific T-cell responses postvaccination.
Ex vivo IFN- ELISPOT assays illustrated that the vaccine had
generated detectable FLR-specific responses in 8/9 vaccine
recipients. Responses were detected in 7/8 of the vaccinees
(#01, #02, #04, #05, #06, #07, and #08) who received 5 g
of peptide and in one vaccinee (#13) who received 50 g of
peptide (Fig. 1A). T-cell data from vaccinee #14 are not pre-
sented (see above). Vaccinees #09 and #14 were the only
vaccinees in whom FLR-specific responses could not be dem-
onstrated postvaccination by ELISPOT assay. However,
PBMC from #08, #10, and #12 weeks were not available for
testing for vaccinee #09, and PBMC from only two time points
(weeks 2 and 4) were available for vaccinee 14 before serocon-
version. Appropriate V TCR sequences were nevertheless
identified in PBMC from vaccinee #09 at week 8 (see below).
No responses were observed in any of the placebo vaccine
recipients (#03 and #10 [Fig. 1] and #011 and #12 [data not
shown]). When the mean responses for the six vaccinees who
received two immunizations were plotted over time, clear
TABLE 2. Injection site reactions and TT titers
Vaccine Vaccinerecipient
Injection site reactiona after: TT titer, IU/ml (wk after
vaccinationb)First vaccination Second vaccination
Peptide
5 g #01 11- by 6.5-cm red warm swelling at day 9,
resolved at day 28
2- to 3-cm mild swelling 0.25 (P), 0.91 (4), 1.1 (8),
1.2 (104)
#02 6-cm swelling at day 5–6, mild discomfort,
resolving at day 14
Slight thickening 1.0 (P), 0.74 (4), 0.73 (8),
0.86 (12)
#04 Slight pain for 24 h, 5- by 4-cm induration at
day 14, itching
No significant reaction 1.6 (P), 1.5 (4), 1.2 (8),
1.3 (12), 1.1 (52)
#05 10- by 8-cm firm warm raised swelling, resolved
at day 7
No significant reaction 0.7 (P), 1.5 (4), 1.5 (8),
1.5 (10), 1.9 (12)
#06 No significant reaction 9-cm swelling at day 3, slightly
tender, resolved at day 5
2.6 (P), 1.5 (4), 2.40 (8),
3.0 (26)
#07 11- by 8-cm raised erythema at day 2, pain,
resolving at day 14
NAc 4.9 (P), 7.0 (4), 5.3 (8),
7.0 (14)
#08 7-cm raised pink warm itchy area at day 3 NA 0.35 (P), 5.3 (4)
#09 10-cm tender raised red swelling at day 2, 2 cm
by day 4
NA 1.7 (P), 1.5 (4), 2.8 (26)
50 g #13 No significant reaction No significant reaction 0.5 (P), 1.1 (4), 1.1 (8),
1.8 (10)
#14 No significant reaction NA 3.0 (P), 3.9 (4), 3.9 (8)
Placebo #03 2- to 3-cm induration, slightly tender for 3 days 5-cm red tender warm swelling at
day 1, 3-cm induration at day
3, resolving at day 18
3.9 (P), 4.5 (4), 2.6 (8),
2.8 (10), 2.2 (12)
#10 Slight tender swelling at day 5 6-cm warm swelling at day 5 0.55 (P), 3.3 (4), 3.6 (52)
#11 2-cm induration, slightly tender at day 14 NA 1.1 (P), 5.9 (4)
#12 No significant reaction 8-cm erythema, itchy, resolved
after day 8
3.7 (P), 3.2 (4), 2.9 (8),
4.6 (156)
a Measurements are diameters.
b P, prevaccination. Boldface indicates TT values above the 5-IU/ml cutoff.
c NA, not applicable because no second vaccination was given.
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postvaccination expansions of T-cell numbers followed by
their expected contraction (22) could be seen (Fig. 1B).
The LDA assays showed vaccine-induced FLR-specific re-
sponses in 3/9 vaccine recipients (#01, #05, and #13), with a
marginal response in vaccinee 2 (Fig. 2). No responses were
detected in the four placebo-vaccinated individuals (#03 and
#10 [Fig. 2] and #11 and #12 [data not shown]).
PBMC from vaccinees 1, 6, and 13 were tested for long-
term FLR-specific memory responses at weeks 412, 523, and
421, respectively, using the cultured ELISPOT method of
Goonetilleke et al. (21). Responses of 0, 92.5, and 95 IFN-
spots per 106 PBMC were obtained, respectively; however, the
latter two did not reach significance over background (data not
shown).
TCR sequence analysis. FLR-specific CD8 T cells in nearly
all HLA B8 EBV-seropositive individuals share the same V
TCR amino acid sequence (3, 52). RT-PCR and sequencing
were therefore used to determine whether FLR vaccination
induced CD8 T cells with this V sequence. PBMC or bulk
culture samples (containing 5 	 106 cells) from six vaccinees
(#01, #05, #06, #07, #09, and #13) and three individuals
receiving the placebo (#10, #11, and #12) taken at various
times (see Fig. 3 legend) were analyzed by RT-PCR. All the
samples from vaccinees produced PCR products that were
detected by ethidium bromide staining (data not shown). In
contrast, detectable PCR products were not generated from
PBMC taken at week 0 from vaccinee #01 or from any of the
six placebo PBMC samples, with the exception of PBMC from
#12 taken at week 2 (data not shown). All samples produced
bright, clear, and consistent PCR products when the TCR
constant-region primers were used (data not shown). PCR
products from no. 12 at week 2 and a selection of products
FIG. 1. Ex vivo IFN- ELISPOT analysis. (A) The vaccine was
administered twice at week 0 and week 8 (	2), except for vaccinees
#07, #08, and #09, who received only the first vaccination (	1).
Vaccinees received a 5-g dose of peptide, except #13, who received
a 50-g dose, and #03 and #10, who received no peptide (placebo).
PBMC from vaccinees collected prior to vaccination (week 0) and at
the indicated number of weeks after the first vaccination were analyzed
by ex vivo IFN- ELISPOT assay using the FLR peptide and frozen
PBMC. Three vaccinees seroconverted asymptomatically within 2
years (#04, #08, and #09), and the time at which serology first indi-
cated EBV seroconversion is indicated with a gray triangle. Vaccine-
induced responses are represented by black bars. Speckled bars illus-
trate responses after EBV seroconversion. Black bars at 2.5 IFN-
spots/106 PBMC represent no significant response and are shown to
indicate that an assay was performed on PBMC collected at that time
point. (B) Mean numbers of IFN- spots ( standard errors) for
vaccinees #01, #02, #04, #05, #06, and #13 (black squares), who
received vaccinations at 0 and 8 weeks (arrows). The mean numbers of
spots for all four placebo recipients are also shown (white squares).
The two groups are significantly different (P  0.041) by analysis of
variance, which included a term for weeks.
FIG. 2. LDA. Fresh PBMC from the same vaccines as described in
the legend to Fig. 1 were analyzed by LDA. Cultures were stimulated
with either autologous LCLs (black bars) or FLR peptide (10 g/ml)
(gray bars) and assessed in 51Cr release assays. Speckled bars illustrate
responses after EBV seroconversion. The time when serology first
indicated EBV seroconversion is indicated with a gray triangle. Bars at
0.4/106 PBMC represent no significant response and are shown to
indicate that an assay was performed on PBMC collected at that time
point.
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from six vaccinees were cloned and sequenced. All clones pro-
viding TCR sequences from all six vaccinees showed the same
V amino acid sequence as that previously published for CD8
T cells recognizing FLR (3), although several different nucle-
otide sequences were seen (Fig. 3). The same nucleotide se-
quence was also found in #09 PBMC at 8 weeks and after EBV
seroconversion at week 104. Two sequences were obtained
from the PCR product from PBMC of the placebo recipient
#12 at week 2 (Fig. 3, #12 w2 Placebo); however, neither
showed any similarity to the consensus sequence. These data
indicate that FLR peptide vaccination of EBV-seronegative
individuals induced CD8 T cells with the same V TCR amino
acid sequence as that seen in the majority of HLA B8 individ-
uals both during primary infection and after EBV seroconver-
sion (52).
FLR-specific T-cell responses post-EBV seroconversion.
Three vaccinees, #04, #08, and #09, seroconverted asymp-
tomatically within 2 years with no lymphocytosis evident at the
time of positive EBV serology (Table 1). These vaccinees
showed FLR-specific T-cell responses of 404, 1,240, and 792
IFN- spots per 106 PBMC after seroconversion (Fig. 1).
These T-cell frequencies are comparable to those found in
other studies using ex vivo ELISPOT analysis of FLR-specific
T-cell responses in healthy EBV-seropositive HLA B8 individ-
uals (32, 58). In our hands such individuals usually give FLR-
specific responses in the range of 100 to 1,100 spots/106 PBMC
in ex vivo IFN- ELISPOT assays (data not shown). The LDA
frequencies following seroconversion (Fig. 2) are also compa-
rable to those found in healthy EBV-seropositive individuals
(11, 12). Analysis with MHC-peptide multimers of FLR-spe-
cific responses in vaccinees #04 and #09 (Fig. 4A, B*0801-
FLR) also showed responses similar to those seen during IM
and in healthy seropositive individuals (24). We were thus
unable to find any evidence that vaccine-primed individuals
were predisposed to abnormally high FLR-specific anemnestic
responses after EBV seroconversion.
Examination of the phenotype of the B*0801-FLR multimer-
positive cells for #04 (week 104) and #09 (week 26) showed
the expected memory phenotype. However, significant propor-
tions (25% and 57%, respectively) were CD45RA positive. For
#09, this percentage dropped to 4% at week 52 (Table 3). In
healthy seropositive individuals and during IM, latent anti-
gen-specific CD8 T cells usually remain CD45RA negative
(16, 24).
Normal acquisition of CD8 T-cell responses to other
epitopes in vaccinees after EBV seroconversion. To determine
whether, after EBV seroconversion, vaccinees developed nor-
mal CD8 T-cell responses to other epitopes or whether vac-
cination causes responses to be dominated by FLR-specific
CD8 T cells, PBMC from vaccinees #04 and #09 were ana-
lyzed with an MHC-peptide multimer for responses to the
HLA B*0801-restricted epitope RAK from the lytic antigen
BZLF1. Vaccinee #04 developed RAK responses (Fig. 4A,
HLA B*0801-RAK) comparable to those seen in individuals
recovering from IM or in individuals latently infected with
EBV (24). Vaccinee 9 showed a clear expansion of RAK-
specific responses at week 26, which fell at week 52 (Fig. 4A,
HLA B*0801-RAK). Similar expansions and contractions of
RAK responses have been well documented for IM patients as
they recover from disease (24). The phenotypes of the HLA
B*0801-RAK pentamer-positive cells were also similar to
those seen in individuals recovering from IM (16, 25) (Table
3, HLA B*0801-RAK). Responses to FLR, the HLA
B*0801-resticted epitope, QAK (from EBNA3), and RAK
could also be detected in PBMC collected 26 and 104 weeks
after immunization for vaccinees #04 and #09, respectively,
using chromium release assays (Fig. 4B). In addition, ELISPOT
assays using week 104 PBMC from vaccinee #08 showed HLA
A2-resticted responses to GLCTLVAML (from BMLF1) as
well as RAK responses similar to those found in healthy sero-
positive individuals (58) (Fig. 4C). Small responses to the HLA
FIG. 3. TCR V sequences postvaccination. Sequences from
cloned PCR products from PBMC or bulk cultures from vaccine re-
cipients taken at the indicated times postvaccination (w, week) are
shown. The frequency with which the indicated sequence was found
over the total number of clones providing TCR sequence is indicated
in the right column. a, from bulk cultures; b, vaccinee #09 had sero-
converted at this time. The consensus sequence for LC13 (3) is shown
at the top together with the germ line gene sequences that are used in
the generation of this CDR3 region. Clear PCR products were ob-
tained from #01 PBMC collected at weeks 2, 10, 26, 68, and 104; from
#01 bulk cultures at week 4; from #05 bulk cultures at week 104; from
#06 PBMC at weeks 2, 12, and 26; from #06 PBMC at weeks 2, 12,
and 26; from #07 PBMC at week 8; from #09 PBMC at weeks 8, 10,
12, and 52; from placebo #12 PBMC at week 2; and from #13 PBMC
at weeks 8 and 10. No detectable PCR products were obtained from
#01 PBMC at week 0 (two samples), placebo #10 PBMC at weeks 2
and 4, placebo #11 PBMC at weeks 2 and 4, and placebo #12 PBMC
at week 12 (data not shown).
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A2-restricted epitopes LLD (28) and CLG (34) were also de-
tected (Fig. 4C). Thus, taken together, these data do not sup-
port the view that single-epitope immunization results in im-
munodominance or immunodomination effects (17) which
would lead to the repression of responses to other epitopes
following seroconversion.
DISCUSSION
Although dendritic cells pulsed with CD8 T-cell epitopes
have been used to treat EBV-positive nasopharyngeal carci-
noma patients (35), to our knowledge the current paper de-
scribes the first CD8 T-cell-based EBV vaccine trial with
EBV-seronegative individuals, and it illustrates that epitope-
based vaccination is mostly well tolerated and immunogenic in
most individuals. The same TCR V sequences that are in-
volved in recognizing FLR presented by EBV-infected cells in
HLA B8 EBV-seropositive individuals (3) were also found in
EBV-seronegative volunteers postvaccination. Importantly,
vaccine-based priming of responses to the single FLR epitope
did not predispose individuals to disease following a primary
EBV infection, indicating that single-epitope immunization is
safe in this context. In addition, neither FLR nor other EBV-
specific CD8 T-cell responses were demonstrably affected in
vaccinees following primary EBV infection, suggesting that
significant immunodominance or immunodomination effects
did not occur (17). Insufficient numbers preclude any formal
assessment of vaccine efficacy. Nevertheless, excluding vac-
cinee 14, who seroconverted near the time of vaccination, 4/4
FIG. 4. CD8 T-cell response of vaccinees after EBV seroconversion.
(A) PBMC from vaccinees (no. 9 and 4) collected at the indicated time
points postvaccination were assessed by FACS using FLR-specific (left
panels, B*0801-FLR) and RAK-specific (right panels, B*0801-RAK)
pentamers (x axis) and anti-CD8 monoclonal antibody (y axis). The
percentage of CD8 T cells that are pentamer positive are indicated in
the top right corner of each panel. (B) Standard chromium release
assay using bulk cultures generated from PBMC from vaccinees #09
(week 52) and #04 (week 104) to asses lytic activity specific for FLR,
QAK, and RAK. (C) Ex vivo IFN- ELISPOT assay using PBMC from
vaccinee #08 (collected at week 104) to asses T-cell responses to the
HLA A*0201-restricted epitopes LLDFVRFMGV (LLD), GLCTL
VAML (GLC), CLGGLLTMV (CLG), ILIYNGWYA (ILI), YLLE
MLWRL (YLL), and YLQQNWWTL (YLQ) and the HLA B*0801-
restricted epitopes FLR, QAK, and RAK.
TABLE 3. Percentages of B*0801-FLR and -RAK tetramer-positive
cells expressing CD27, CD28, CD45RA, CD45RO, and CD62L
Vaccinee Tetramer(wk)
%
CD8 CD27 CD28 CD45RA CD45RO CD62L
B*0801- #04 (104) 0.34a 97 99 25 82 24
FLR #09 (26) 0.48a 97 99 57 91 58
#09 (52) 0.7a 98 99 4 86 48
#01 (NA)b 1.3 89 83 5 92 47
B*0801- #04 (104) 4.37a 87 99 40 42 24
RAK #09 (26) 12.42a 79 99 26 47 28
#09 (52) 8.52a 89 99 28 34 31
#01 (NA) 3.41 90 97 38 61 40
a As shown in Fig. 3A.
b Healthy seropositive donor. NA, not applicable.
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of the peptide vaccine recipients who seroconverted failed to
develop IM, whereas 1/2 of the placebo-vaccinated individuals
who seroconverted developed IM. Published studies on the
incidence of IM among young adults experiencing primary
EBV seroconversion show a range from 25 to 74% (19).
The most common side effect in our study was inflammation
and discomfort at the site of injection (Table 2), an observation
also made in previous trials using this adjuvant (36, 62). The
side effects were similar in the peptide vaccine and placebo
groups (Table 2), indicating that they were unrelated to the
peptide component of the formulation. Following a pretrial
vaccination of an HLA B8 EBV-seropositive individual with
the 5-g FLR vaccine, TT titers rose from 8.3 to 50,000
IU/ml. This was associated with a severe injection site reaction,
consisting of a 15-cm-diameter erythema and induration, with
suppuration lasting 2 months (data not shown). TT is thus
the likely cause of injection site reactions (27, 33), despite the
fact that only 1/10th the amount of TT in the conventional
TT-alum vaccine was delivered. The 5-IU/ml cutoff adopted
for this trial was implemented to minimize the risk of such
inflammatory responses. However, this meant that 45% of
volunteers could not enter the trial, and 3/14 vaccinees did not
receive a second dose of vaccine (Table 2). TT thus does not
appear to be a good choice for providing CD4 T-cell help in
such vaccines, although adequate help for CD8 induction was
likely provided by the TT, since all vaccinees increased their
TT titer and/or showed a pronounced reaction to the vaccine.
Such responses/reactions are likely due to activation of TT-
specific CD4 T cells (7), which should provide the necessary
help for CD8 T-cell induction (6, 48). However, alternative
proteins or peptides that have not previously been seen by the
patient’s immune system might provide sufficient help without
the associated anamnestic inflammatory response (42). gp350
from EBV is clearly an obvious candidate (40).
The presence of CD45RA-positive latent-antigen-specific
CD8 T cells during acute asymptomatic seroconversions in
vaccinees #04 and #09 (Table 3) contrasts with the observa-
tion that such cells are usually CD45RA negative during IM
and in healthy seropositive individuals (16, 24). Such CD45RA,
CD45R0 double-positive memory cells have been reported
previously after primary human cytomegalovirus infection
(63). It is unclear whether this is a general feature of acute
asymptomatic seroconversions or due to vaccination. The ex-
pansion of RAK-specific CD8 T cells in #09 at week 26 (Fig.
4A) in the absence of a lymphocytosis was also unexpected,
since a previous study has demonstrated no major perturba-
tions in the blood TCR repertoire in three out of four individ-
uals undergoing asymptomatic seroconversion (53). The TCR
repertoire recognizing the dominant RAK epitope can be di-
verse (51), so conceivably TCR repertoire analysis may not
detect such expansions. This RAK expansion is unlikely to be
a result of FLR vaccination and therefore indicates that lytic
antigen-specific expansions can occur during asymptomatic se-
roconversions.
Due to the HLA diversity across human populations, we
have estimated that about 25 CD8 T-cell epitopes would be
needed to cover 90% of individuals in Western countries.
Although complex peptide mixtures can be effectively codeliv-
ered in water-in-oil adjuvants (20), manufacture of a vaccine
with so many individual components is difficult. EBV peptide-
based vaccines with fewer epitopes might be envisaged for
PTLD patients, where the HLA is often known, or for IM if
specific populations are targeted or where reduced population
coverage is acceptable. Combining large numbers of epitopes
for an EBV vaccine might be achieved using the polyepitope or
polytope approach (55, 60), which has recently shown some
success in human trials (21). The data presented here suggest
that an epitope-based approach for EBV vaccines is safe and
does not appear to predispose individuals to immunological
problems after EBV infection.
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